Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Ipsen
Woman and Man Max 99 years
Beaufour Ipsen Pharma-Ipsen Biotech Department
Update Il y a 4 ans
Phase III multicentre, Randomised, Double Blind, Comparative study to assess the efficacy and safety of lanreotide 30mg versus placebo as a palliative treatment of clinical symptoms associated with intestinal obstruction due to peritoneal carcinomatosis in inoperable patients
The primary objective of this study is to assess the efficacy of lanreotide 30 mg as compared to placebo to relieve clinical symptoms due to small bowel obstruction in inoperable patients with periton...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Ipsen Innovation
Update Il y a 4 ans
A study to investigate DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination as a result of spinal cord injury or multiple sclerosis
• To assess the efficacy of two Dysport® doses (600 units (U) and 800 U), compared to placebo in reducing UI from Baseline to Week 6 following the first investigational medicinal product (IMP) adminis...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Ipsen Limited
Update Il y a 4 ans
A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder
To assess the effect of treatment with three doses of botulinum toxin type-A (Dysport®) versus placebo on the number of episodes of urgency and frequency of micturition experienced in continent female...
Country
None
organs
None
Specialty
None
Closed trial
More information
Beaufour Ipsen Pharma
Update Il y a 4 ans
AN EXPLORATORY, OPEN, TWO-ARM, MATCH-CONTROL, RANDOMISED AND STRATIFIED PILOT PHASE II STUDY ASSESSING THE PREVENTION OF THE ADVERSE EFFECTS OF LONG-TERM HIGH-DOSE GLUCOCORTICOID THERAPY BY GROWTH HORMONE (NutropinAqTM) ADMINISTERED BY SUB-CUTANEOUS ROUTE IN CHILDREN WITH CHRONIC DISEASE
The primary objective of the study is to determine whether the administration of growth hormone will result in the prevention/reduction of adverse effects induced by long-term high-dose glucocorticoid...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Ipsen Ltd
Update Il y a 4 ans
To assess & compare the impact on disease control & patient & practitioner experience between the 6-monthly study drug & available 3-monthly injections. Comparison of the proportions of patients medically castrated & their PSA levels at 6 and 12 months between the 6-monthly study drug & 3-monthly injections. Review of patient satisfaction & preference for the 6-monthly study drug compared to 3-monthly injections & explore the effects of the 6-monthly study drug on the patients’ Quality of Life
Primary Study Objective The primary objective of this study is to demonstrate non-inferiority of Decapeptyl SR 22.5mg to a standard 3-monthly LHRH agonist in maintaining biochemical castration (testo...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Ipsen Innovation
Update Il y a 4 ans
The purpose of this clinical study is to assess safety and efficacy of different doses of Dysport® RU (RU= Ready to Use), a new formulation of a drug called Dysport®, which is used for the improvement in the appearance of glabellar lines (lines that appear on the forehead between the eyebrows). Additionally, the study will aim to establish the dose of Dysport® RU, which is equivalent in terms of safety and efficacy to the optimal dose of 50 U of Dysport®
The primary objective is to assess the dose response versus placebo of a single treatment with Dysport RU used for the improvement in the appearance of moderate to severe glabellar lines at maximum fr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Ipsen
Update Il y a 4 ans
Étude CLARINET FORTE : étude de phase 2, évaluant l’efficacité et la tolérance du lanreotide autogel® 120 mg administré tous les 14 jours, chez des patients ayant un cancer du pancréas ou une tumeur neuroendocrine du tube digestif, non résécable localement avancé ou métastatique en progression après un traitement standard par lanreotide autogel® 120 mg. [essai clos aux inclusions]
Les tumeurs neuroendocrines du pancréas ou de l’intestin moyen sont des tumeurs rares qui ont une progression lente. Les thérapies disponibles pour traités ces tumeurs sont limitées, d’où le besoin de...
Country
France
organs
Pancréas
,
Tumeurs endocrines digestives
Specialty
Hormonothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Ipsen Farmaceutica b.v
Update Il y a 4 ans
Predictive value of the IGF-I generation test to predict the results of growth hormone treatment in short children
Assessment of the value of the short-term (2 weeks) response of IGF-I (peak IGF-I SDS) to GH in a dosage of 1.4 mg/m2/day (as part of a dose-escalation IGF-I generation test) in comparison to baseline...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Ipsen Innovation
Update Il y a 4 ans
Phase III, multicentre study assessing the efficacy and safety of Dysport compared to a Placebo for the treatment of upper limb spasticity in adult patients with hemiparesis
The primary study objective is to assess the efficacy of Dysport compared to placebo in reducing upper limb muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic br...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Ipsen Pharma GmbH
Update Il y a 4 ans
Study to investigate the combination of Lanreotide Autogel 120mg and Temozolomid in patients with WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMOURS
The primary study objective is to evaluate the efficacy of Lanreotide Autogel (ATG) 120 mg in combination with Temozolomide in patients with functioning as well as non-functioning, progressive, gastro...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
Next